Swiss Re’s Pfizer PFE Stock Holding History

Swiss Re’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$124K	Buy	5,152 +4,376	+564%	+$114K	0.01%	197
2026 Q1	$21.8K	Hold	776	–	–	0.13%	118
2025 Q4	$19.3K	Buy	+776	New	+$19.6K	﹤0.01%	133

Other funds holding PFE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Swiss Re's PFE Position: Q2 2026 in Review

Swiss Re increased its Pfizer (PFE) stake by 564% in Q2 2026, buying an estimated $114K and bringing the position to 5,152 shares worth $124K. The position accounts for 0.01% of the portfolio, ranked #197.

Swiss Re first reported a position in PFE in Q4 2025 and has held it in 3 quarters since. 2,827 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

Swiss Re held 5,152 shares of Pfizer worth $124K as of Q2 2026.
Swiss Re bought 4,376 Pfizer shares in Q2 2026, an estimated $114K.
Pfizer made up 0.01% of Swiss Re's portfolio in Q2 2026, its #197 holding.
Swiss Re first reported a position in Pfizer in Q4 2025 and has held it in 3 quarters since.
2,827 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Swiss Re's 13F filing for Q2 2026, filed 11 Aug 2026.